e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Why did they get XDR TB ?
V. Cojocariu, A. Sorete Arbore, T. Mihaescu (Iasi, Romania)
Source:
Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Session:
Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Session type:
Poster Discussion
Number:
3302
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Cojocariu, A. Sorete Arbore, T. Mihaescu (Iasi, Romania). Why did they get XDR TB ?. Eur Respir J 2011; 38: Suppl. 55, 3302
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Linezolid in the treatment of patients with MDR TB and XDR TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Extensively drug-resistant (XDR) pulmonary tuberculosis in HIV negative cases
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Who is responsible for MDR- TB?
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015
Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis
Source: Eur Respir J, 54 (1) 1802208; 10.1183/13993003.02208-2018
Year: 2019
Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study
Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis
Year: 2008
Analysis of multidrug-resistant tuberculosis
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1
Year: 2014
Treatment results in patients with XDR tuberculosis in Ukraine
Source: Eur Respir J 2007; 30: Suppl. 51, 272s
Year: 2007
Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014
Multidrug-resistant tuberculosis (MDR-TB)
Source: Breathe 2010; 6: 283
Year: 2010
Is prevalence of MDR TB and XDR TB decreasing in a tertiary care hospital in India?
Source: International Congress 2017 – MDRTB: detection and management
Year: 2017
Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Prevalence of MDR TB and XDR TB in a tertiary care hospital in India
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis
Year: 2008
Changing prevalence of MDR TB and XDR TB in a tertiary care hospital in India
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I
Year: 2013
The global risk of dying from multidrug-resistant tuberculosis (MDR-TB)
Source: International Congress 2014 – Tuberculosis epidemiology: novel features
Year: 2014
MDR TB treatment in prison
Source: Eur Respir J 2002; 20: Suppl. 38, 614s
Year: 2002
Multidrug-resistant tuberculosis (MDR-TB) and HIV co-infection in Romania
Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Year: 2011
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB)
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Determinants of multidrug-resistant tuberculosis (MDR-TB) in Belarus
Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview
Year: 2012
Is standardized treatment appropriate for non-XDR multiple drug resistant TB?
Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2008
The MTBDRplus 2.0 for rapid diagnosis of multidrug-resistant tuberculosis among patients with high risk of TB resistance
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept